华西医学

华西医学

前列腺影像报告及数据系统 V2 的构建及在前列腺癌多参数 MRI 诊断中的初步评价

查看全文

前列腺癌发病率居老年男性恶性肿瘤第 2 位。多参数 MRI(multi-parametric MRI,Mp-MRI)是前列腺癌检出、分期以及选择治疗方案的重要依据。为规范前列腺 MRI 数据采集、判读和报告,欧洲泌尿生殖放射学会于 2012 年发布前列腺影像报告及数据系统(Prostate Imaging Reporting and Data System,PI-RADS)。由于在应用过程中存在一定的局限性,美国放射学会、欧洲放射学会等组成的联合委员会于 2014 年发布了新版本 PI-PADS V2。近年来学者们围绕其对前列腺癌诊断的有效性、准确性及一致性等方面展开了一些研究。该文对 PI-RADS V2 构建及在前列腺癌 Mp-MRI 诊断中的初步评价进行了综述。

The incidence of prostate cancer ranks the second in malignant tumors among elderly males. Multi-parametric MRI (Mp-MRI) is an important means for detection, staging, and grading of prostate cancer. In order to standardize the collection, interpretation, and reporting of prostate MRI data, the European Urogenital Radiology Society launched the Prostate Imaging Reporting and Data System (PI-RADS) in 2012. Due to some limitations in the application process, the Joint Committee of the American Society of Radiology and the European Society of Radiology issued an updated version of PI-PADS V2 in 2014. In recent years, some studies have been carried out on the effectiveness, accuracy, and consistency of the diagnosis of prostate cancer. This article will review the application and research status of PI-RADS V2 system in the diagnosis of Mp-MRI for prostate cancer.

关键词: 前列腺癌; 多参数磁共振成像; 前列腺影像报告及数据系统

Key words: Prostate cancer; Multi-parametric magnetic resonance imaging; Prostate Imaging Reporting and Data System V2

登录后 ,请手动点击刷新查看全文内容。 没有账号,
1. Maddams J, Utley M, Møller H. Projections of cancer prevalence in the United Kingdom, 2010-2040. Br J Cancer, 2012, 107(7): 1195-1202.
2. Levine MA, Ittman M, Melamed J, et al. Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer. J Urol, 1998, 159(2): 471-475.
3. Kvåle R, Møller B, Wahlqvist R, et al. Concordance between Gleason scores of needle biopsies and radical prostatectomy specimens: a population-based study. BJU Int, 2009, 103(12): 1647-1654.
4. Pinto PA, Chung PH, Rastinehad AR, et al. Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. J Urol , 2011, 186(4): 1281-1285.
5. Moore CM, Robertson NL, Arsanious NA, et al. Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. Eur Urol, 2013, 63(1): 125-140.
6. Turkbey B, Choyke PL. Multiparametric MRI and prostate cancer diagnosis and risk stratification. Curr Opin Urol, 2012, 22(4): 310-315.
7. Ahmed HU, Kirkham A, Arya M, et al. Is it time to consider a role for MRI before prostate biopsy?. Nat Rev Clin Oncol, 2009, 6(4): 197-206.
8. Barentsz JO, Richenberg J, Clements R, et al. ESUR prostate Mr guidelines 2012. Eur Radiol, 2012, 22(4): 746-757.
9. Weinreb JC, Barentsz JO, Choyke PL, et al. PI-RADS prostate imaging - reporting and data system: 2015, version 2. Eur Urol, 2016, 69(1): 16-40.
10. Siddiqui MM, Rais-Bahrami S, Turkbey B, et al. Comparison of Mr/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA, 2015, 313(4): 390-397.
11. Turkbey B, Mani H, Aras O, et al. Prostate cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance?. Radiology, 2013,268(1):144-152.
12. Bott SR, Ahmed HU, Hindley RG, et al. The index lesion and focal therapy: an analysis of the pathological characteristics of prostate cancer. BJU Int, 2010, 106(11): 1607-1611.
13. Barrett T, Vargas HA, Akin O, et al. Value of the hemorrhage exclusion sign on T1-weighted prostate Mr images for the detection of prostate cancer. Radiology, 2012, 263(3): 751-757.
14. Turkbey B, Merino MJ, Gallardo EC, et al. Comparison of endorectal coil and nonendorectal coil T2W and diffusion-weighted MRI at 3 Tesla for localizing prostate cancer: correlation with whole-mount histopathology. J Magn Reson Imaging, 2014, 39(6): 1443-1448.
15. Rosenkrantz AB, Taneja SS. Radiologist, be aware: ten pitfalls that confound the interpretation of multiparametric prostate MRI. AJR Am J Roentgenol, 2014, 202(1): 109-120.
16. Oto A, Kayhan A, Jiang Y, et al. Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced Mr imaging. Radiology, 2010, 257(3): 715-723.
17. Thörmer G, Otto J, Reiss-Zimmermann M, et al. Diagnostic value of ADC in patients with prostate cancer: influence of the choice of b values. Eur Radiol, 2012, 22(8): 1820-1828.
18. Litjens GJ, Hambrock T, Hulsbergen-Van De Kaa C, et al. Interpatient variation in normal peripheral zone apparent diffusion coefficient: effect on the prediction of prostate cancer aggressiveness. Radiology, 2012, 265(1): 260-266.
19. Sasaki M, Yamada K, Watanabe Y, et al. Variability in absolute apparent diffusion coefficient values across different platforms may be substantial: a multivendor, multi-institutional comparison study. Radiology, 2008, 249(2): 624-630.
20. 李拔森, 王良. 第二版前列腺影像报告和数据系统(PI-RADS)解读. 中华放射学杂志, 2015, 49(10): 798-800.
21. Iwazawa J, Mitani T, Sassa S, et al. Prostate cancer detection with MRI: is dynamic contrast-enhanced imaging necessary in addition to diffusion-weighted imaging? Diagn Interv Radiol, 2011, 17(3): 243-248.
22. Haider MA, Chung P, Sweet J, et al. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys, 2008, 70(2): 425-430.
23. Barrett T, Davidson SR, Wilson BC, et al. Dynamic contrast enhanced MRI as a predictor of vascular-targeted photodynamic focal ablation therapy outcome in prostate cancer post-failed external beam radiation therapy. Can Urol Assoc J, 2014, 8(9/10): E708-E714.
24. Rouvière O, Girouin N, Glas L, et al. Prostate cancer transrectal HIFU ablation: detection of local recurrences using T2-weighted and dynamic contrast-enhanced MRI. Eur Radiol, 2010, 20(1): 48-55.
25. Baco E, Rud E, Vlatkovic L, et al. Predictive value of magnetic resonance imaging determined tumor contact length for extracapsular extension of prostate cancer. J Urol, 2015, 193(2): 466-472.
26. Ohori M, Scardino PT, Lapin SL, et al. The mechanisms and prognostic significance of seminal vesicle involvement by prostate cancer. Am J Surg Pathol, 1993, 17(12): 1252-1261.
27. 郭雪梅, 王霄英, 吴冰, 等. 前列腺外周带癌扩散加权成像诊断标准. 中国医学影像技术, 2009, 25(7): 1235-1238.
28. Barentsz J, Villers A, Schouten M. ESUR prostate MR guidelines. Author reply.[J]. European Radiology, 2013, 23(8): 2322-2323.
29. Feng ZY, Wang L, Min XD, et al. Prostate cancer detection with multiparametric magnetic resonance imaging: prostate imaging reporting and data system version 1 versus version 2. Chin Med J, 2016, 129(20): 2451-2459.
30. 王希明, 包婕, 朱默, 等. 第一版和第二版前列腺影像报告和数据系统评分对移行带前列腺癌的诊断价值. 中华放射学杂志, 2017, 51(6): 427-431.
31. 李拔森, 王良, 邓明, 等. 多参数MRI前列腺影像报告和数据系统评分与经直肠超声引导下穿刺病理的相关性分析[J]. 磁共振成像, 2016, 7(5):321-326.
32. Renard-Penna R, Mozer P, Cornud F, et al. Prostate imaging reporting and data system and likert scoring system: multiparametric Mr imaging validation study to screen patients for initial biopsy. Radiology, 2015, 275(2): 458-468.
33. 牛翔科, 刘伟, 肖建明, 等. PI-RADS v2在前列腺癌中的诊断价值分析. 四川大学学报: 医学版, 2016, 47(5): 796-799.
34. 中华放射学杂志前列腺疾病诊疗工作组, 中华放射学杂志编辑委员会. 前列腺癌MR检查和诊断共识. 中华放射学杂志, 2014, 48(7): 531-534.
35. 张永胜, 龚向阳, 陈祖华, 等. 前列腺影像报告和数据系统的研究进展. 实用放射学杂志, 2016, 32(6): 959-962.
36. Kuru TH, Saeb-Parsy K, Cantiani A, et al. Evolution of repeat prostate biopsy strategies incorporating transperineal and MRI-TRUS fusion techniques. World J Urol, 2014, 32(4): 945-950.
37. Sharma S. Imaging and intervention in prostate cancer: Current perspectives and future trends. Indian J Radiol Imaging, 2014, 24(2): 139-148.